

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

June 7, 2024

**CSO Daisuke Morishita to Speak at the 28<sup>th</sup> Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer**

Kanagawa, Japan,

June 7, 2024 – Chordia Therapeutics K.K. (Head Office: Fujisawa City, Kanagawa Prefecture; President: Hiroshi Miyake) is pleased to announce that Daisuke Morishita, CSO of Chordia Therapeutics, will speak at the 28<sup>th</sup> Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer scheduled to be held on June 19-21, 2024.

**About the 28<sup>th</sup> Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer**

The theme of this year's scientific meeting is "The Frontiers of Cancer Research and Drug Development with All-out Efforts. In light of the situation where drug discovery research and development is progressing by combining the wisdom of various fields, including information science, amid the diversification of drug discovery modalities, the symposium will be held in succession to the "Symposium for Women Scientists" and "Industry-Academia Collaboration Symposium," which have been held continuously at previous scientific meetings, and will also include the introduction of new technologies for the development of new cancer therapeutics. The symposium is also planned to include the introduction of new technologies for the development of new cancer drugs.

**About Chordia Therapeutics**

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia's lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017

Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,  
Kanagawa 251-0012, Japan

Representative: Hiroshi Miyake, Representative Director

Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR Mizobe: [ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)